Cemiplimab +/- Fianlimab Post Y90 Radioembolization in Patients With Hepatocellular Carcinoma

NCT07365839 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: Arm 1 cemiplimab
DRUG: Arm 2 cemiplimab and fianlimab

Sponsor

Virginia Commonwealth University

Collaborators

[object Object]